Cover Image
市場調查報告書

immatics biotechnologies GmbH:產品平台分析

Immatics Biotechnologies GmbH - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 199711
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
immatics biotechnologies GmbH:產品平台分析 Immatics Biotechnologies GmbH - Product Pipeline Review - 2016
出版日期: 2016年02月24日 內容資訊: 英文 46 Pages
簡介

immatics biotechnologies GmbH是使用新的技術來開發癌症治療藥之臨床階段生物醫藥品企業。

本報告提供immatics biotechnologies GmbH的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

immatics biotechnologies GmbH的基本資料

immatics biotechnologies GmbH概要

  • 主要資訊
  • 企業資料

immatics biotechnologies GmbH:R&D概要

  • 主要的治療範圍

immatics biotechnologies GmbH:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

immatics biotechnologies GmbH:開發中產品概況

  • 後期開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

immatics biotechnologies GmbH:藥物簡介

  • IMA-901
  • IMA-910
  • IMA-950
  • IMA-962

immatics biotechnologies GmbH:開發平台分析

  • 各給藥途徑
  • 各分子類型

immatics biotechnologies GmbH:最近的開發平台趨勢

immatics biotechnologies GmbH:企業發表

immatics biotechnologies GmbH:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07961CDB

Summary

Global Markets Direct's, 'Immatics biotechnologies GmbH - Product Pipeline Review - 2016', provides an overview of the immatics biotechnologies GmbH's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by immatics biotechnologies GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of immatics biotechnologies GmbH
  • The report provides overview of immatics biotechnologies GmbH including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses immatics biotechnologies GmbH's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features immatics biotechnologies GmbH's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate immatics biotechnologies GmbH's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for immatics biotechnologies GmbH
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding immatics biotechnologies GmbH's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Immatics Biotechnologies GmbH Snapshot
    • Immatics Biotechnologies GmbH Overview
    • Key Information
    • Key Facts
  • Immatics Biotechnologies GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • Immatics Biotechnologies GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Immatics Biotechnologies GmbH - Pipeline Products Glance
    • Immatics Biotechnologies GmbH - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Immatics Biotechnologies GmbH - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Immatics Biotechnologies GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Immatics Biotechnologies GmbH - Drug Profiles
    • IMA-901
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMA-910
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • APVAC-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • APVAC-2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMA-950
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMA-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMA-102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMA-201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMA-202
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMA-203
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMA-300
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMA-301
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Solid Tumors
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Immatics Biotechnologies GmbH - Pipeline Analysis
    • Immatics Biotechnologies GmbH - Pipeline Products by Target
    • Immatics Biotechnologies GmbH - Pipeline Products by Route of Administration
    • Immatics Biotechnologies GmbH - Pipeline Products by Molecule Type
  • Immatics Biotechnologies GmbH - Recent Pipeline Updates
  • Immatics Biotechnologies GmbH - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Immatics Biotechnologies GmbH, Key Information
  • Immatics Biotechnologies GmbH, Key Facts
  • Immatics Biotechnologies GmbH - Pipeline by Indication, 2016
  • Immatics Biotechnologies GmbH - Pipeline by Stage of Development, 2016
  • Immatics Biotechnologies GmbH - Monotherapy Products in Pipeline, 2016
  • Immatics Biotechnologies GmbH - Partnered Products in Pipeline, 2016
  • Immatics Biotechnologies GmbH - Partnered Products/ Combination Treatment Modalities, 2016
  • Immatics Biotechnologies GmbH - Out-Licensed Products in Pipeline, 2016
  • Immatics Biotechnologies GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Immatics Biotechnologies GmbH - Phase III, 2016
  • Immatics Biotechnologies GmbH - Phase II, 2016
  • Immatics Biotechnologies GmbH - Phase I, 2016
  • Immatics Biotechnologies GmbH - Preclinical, 2016
  • Immatics Biotechnologies GmbH - Discovery, 2016
  • Immatics Biotechnologies GmbH - Pipeline by Target, 2016
  • Immatics Biotechnologies GmbH - Pipeline by Route of Administration, 2016
  • Immatics Biotechnologies GmbH - Pipeline by Molecule Type, 2016
  • Immatics Biotechnologies GmbH - Recent Pipeline Updates, 2016
  • Immatics Biotechnologies GmbH, Subsidiaries

List of Figures

  • Immatics Biotechnologies GmbH - Pipeline by Indication, 2016
  • Immatics Biotechnologies GmbH - Pipeline by Stage of Development, 2016
  • Immatics Biotechnologies GmbH - Monotherapy Products in Pipeline, 2016
  • Immatics Biotechnologies GmbH - Pipeline by Route of Administration, 2016
  • Immatics Biotechnologies GmbH - Pipeline by Molecule Type, 2016
Back to Top